2020-2027 Analysis and Review Delapril Hydrochloride Market

Delapril Hydrochloride Market

Delapril Hydrochloride Market By Clinical Application (Hypertension and Type 2 Diabetes with Hypertension), By Treatment Regimen (Monotherapy and Combination Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

15-05-2020 REP-HC-5086 40 Tables 110 pages Format

The delapril hydrochloride market was valued at USD 326.4 Mn by 2019. A significant increase in the early onset of hypertension in the young adult population primarily determines its market growth. Furthermore, the constant increase in the reported cases of hypertension in type 2 diabetes patients worldwide further accentuates the delapril hydrochloride market growth.

Delapril Hydrochloride Market

Delapril hydrochloride is also called as alindapril is a potent antihypertensive agent by blocking the conversion of angiotensin 1 to angiotensin 2, as a monotherapy it is taken orally as 15mg & 30mg tablets. The dose of manidipine 10 mg/delapril 30mg combination is effective in type 2 diabetic hypertensive patients. Delapril 30mg/indapamide 2.5mg is effective in patients having a greater risk of cerebrovascular stroke during their lifetime.

The major segments related to the delapril hydrochloride market are: 

By Clinical Application (2017–2027; US$ Mn)

Hypertension

Type 2 Diabetes with Hypertension

By Treatment Regimen (2017–2027; US$ Mn)

Monotherapy

Combination Therapy

Geography Segment (2017–2027; US$ Mn)

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global delapril hydrochloride market
  • The overall segmentation of the delapril hydrochloride market, by clinical application, treatment regimen, and geography is minutely studied. Hypertension and combination therapy are dominating the clinical application and treatment regimen segments respectively
  • A constant rise in the number of people suffering from hypertension worldwide

Significant increase in hypertension in people with type 2 diabetes further accentuate the delapril hydrochloride market growth

Report gist?

  • The study of the global delapril hydrochloride market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and treatment regimen and categorization of the same at geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of delapril hydrochloride owing to the rising prevalence of hypertension worldwide
  • The report will benefit formulation scientist engaged in the development of combination therapy for its therapeutic efficacy in type 2 diabetes patients with hypertension
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to delapril hydrochloride market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Hypertension is currently dominating the clinical application segment for the delapril hydrochloride market. As per the latest research citings provided by the World Health Organization (WHO), approximately 1.13 billion people are suffering from hypertension worldwide. It is estimated that fewer than 1 in 5 hypertensive patients have the problem under control, thus making hypertension as one of the leading causes of premature death worldwide. Type 2 diabetes with hypertension is estimated to register rampant market growth during the forecast period. According to the statistics provided by the American Diabetes Association (ADA), it is estimated that approximately 60% of the type 2 diabetes patients report suffering from hypertension in later part of their life. The primary causative agents are obesity, increasing consumption of alcohol and tobacco, stress, etc. 

In the present scenario the combination therapy is the largest and fastest segment in the delapril hydrochloride market. It is a well-known fact that a combination of angiotensin-converting enzyme blocker and a potent diuretic (delapril/indapamide) is effective in patients having a greater risk of suffering from cerebrovascular stroke in the near future. The combination of manidipine/delapril is widely used to provide nephroprotection in type 2 diabetes patients suffering from hypertension. Monotherapy of delapril is currently used in few countries in the European countries such as Italy, Spain, and Germany, etc. owing to its ability to reduce the mortality rate associated with hypertension in the geriatric population. 

Europe is presently leading the geography segment for the delapril hydrochloride market. Early-onset of hypertension in the young adult population primarily drives the market growth. The causative risk factors associated with hypertension are obesity, sedentary lifestyle, unhealthy diet, stress, etc. As per the latest research citings presented by the European Heart Network each year cardiovascular disease is responsible for the death of approximately 3.9 million people in the European Union region. Affordable reimbursement scenario and favorable regulatory environment provided by the European Medical Agency (EMA), for the manufacturing and sale of delapril hydrochloride bolsters its market growth in the region. Delapril hydrochloride is not available in North America. Asia Pacific is anticipated to be the fastest-growing regional segment for the delapril hydrochloride market. The rising prevalence of type 2 diabetes with hypertension complications in the elderly population primarily determines the delapril hydrochloride market growth in the region. Developing healthcare infrastructure and the presence of a well-developed generic drug market further bolster the market growth in Asia Pacific.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.